Kailera Therapeutics (KLRA) said Monday it has closed its initial public offering of about 44.9 million shares, including the exercise in full by the underwriters of an option to buy nearly 5.9 million additional shares, at $16 per share, for gross proceeds of $718.8 million.
All of the shares were offered by the company, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments